KYTX vs. HLVX, NVAX, RGNX, PRME, CRGX, EXAI, MESO, CABA, RLAY, and VALN
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include HilleVax (HLVX), Novavax (NVAX), REGENXBIO (RGNX), Prime Medicine (PRME), CARGO Therapeutics (CRGX), Exscientia (EXAI), Mesoblast (MESO), Cabaletta Bio (CABA), Relay Therapeutics (RLAY), and Valneva (VALN). These companies are all part of the "biological products, except diagnostic" industry.
Kyverna Therapeutics (NASDAQ:KYTX) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.
Kyverna Therapeutics' return on equity of 0.00% beat HilleVax's return on equity.
Kyverna Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 237.68%. HilleVax has a consensus target price of $30.67, suggesting a potential upside of 127.50%. Given Kyverna Therapeutics' higher possible upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than HilleVax.
In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 4 articles in the media. HilleVax's average media sentiment score of 0.50 beat Kyverna Therapeutics' score of 0.27 indicating that HilleVax is being referred to more favorably in the news media.
Kyverna Therapeutics has higher revenue and earnings than HilleVax.
18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 29.3% of HilleVax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
HilleVax received 3 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users.
Summary
Kyverna Therapeutics beats HilleVax on 6 of the 10 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
